Laidlaw Capital Markets is Lead Manager in aTyr Pharma’s (LIFE) $86,250,000. Offering.
Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma’s (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC.
Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).
The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for BioSig over the course of our decade long relationship and look forward to watch the company continue to execute.
Read Article: https://ir.biosig.com/press-releases/detail/278/biosig-announces-closing-of-public-offering-of-common-stock
How advisor platforms are changing the offshore industry
Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for advisors who opt for this independent model?
The entrepreneurial spirit is strong in the advisory industry, with a growing number of international advisors now making the jump to independence. But launching an RIA can prove a time-consuming and costly venture that also requires negotiating crucial third-party agreements with a range of service providers.
Read Full Article Here
Laidlaw expands international business with new Miami-area office
Laidlaw Wealth Management has hired an advisor from Wells Fargo’s international unit in Miami as the firm looks to expand its coverage of Latin America with the opening of a new office. John Cross joined the firm on May 5 after having spent nearly seven years at the wirehouse’s offices in Coral Gables, according to his BrokerCheck profile. He oversees around $100m in assets for clients based mostly in Argentina as well as in the US.
Read Full Article Here
Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $125,000,000 Follow-On Offering for Aldeyra Therapeutics.
Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel Aldeyra’s excellent execution in developing its pipeline and delivering results for patients and investors.
Read Article: Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
From globenewswire.com:
Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing as well as recent scientific developments, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ: HOTH).
Read full article: Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.
The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has been a partner for years now and we are excited for their continued success.
Click the link below for additional information:
Laidlaw Venture Partners Portfolio Company, AerWave Medical, Inc., Closes $4,000,000 Series A Financing Round.
From globenewswire.com:
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.
Click the link below for additional information:
Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals
The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with the company and we look forward to their continued success.
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.
From globenewswire.com:
Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors.
As a global industry leader, Mr. Zook brings years of strategic experience to Voltron Therapeutics and is expected to be instrumental in the further development and eventual commercialization of its Self Assembling Vaccine (SAV) platform, and products such as the Covid-19 vaccine, HaloVax™ and cancer immunotherapy.
Read full article: Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman (globenewswire.com)